Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLFS vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

DXR Overall Winner 6-Pillar Tally: BLFS 3 – 3 DXR Matrix Metrics: BLFS 4 – 6 DXR

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over BioLife Solutions Inc. (BLFS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLFS vs DXR
BLFS NASDAQ
BioLife Solutions Inc.
Electromedical & Electrotherapeutic Apparatus
$38.61
+3.51% 1D
Market Cap $1.8B
TTM Revenue $107M
Forward P/E 117.0x
Beta / 30D Vol 1.05β · 31% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 27.0 Fund 46.0 Flow 59.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.2% over 20 days), RSI 61
RSI-14: 60.5 · SMA20: $37.08 · SMA50: $35.70
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (BLFS 3 – 3 DXR)

Columns: Metric · BLFS · DXR
1. Valuation Multiples DXR
Forward P/E 117.0x 64.5x
Trailing P/E 37.3x 7.7x
PEG Ratio N/M N/M
EV / Revenue 17.0x N/M
2. Growth & Scale DXR
Revenue Growth (YoY) +21.5% +25.5%
Earnings Growth (YoY) -13.9% +329.3%
TTM Revenue (USD) $107M $31,360
Market Cap $1.8B $49.5M
3. Profitability & Quality DXR
Gross Margin 63.6% 100.0%
Operating Margin 6.0% -5894.3%
Net Profit Margin 54.4% 19861.4%
Return on Equity (ROE) 12.8% 14.2%
4. Balance Sheet & Cash Flow BLFS
Cash Generation (TTM) -$2.2M N/A
Cash Flow Margin -2.1% N/A
Net Cash / Leverage $8.3M Net Cash $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLFS
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 40.1% (6th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BLFS
OpEx & R&D Intensity 57.6% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLFS (4) vs DXR (6)
Institutional Metric BLFS DXR Criterion Row Edge
Market Capitalization
Scale
$1.8B $49.5M Larger Scale BLFS
Trailing P/E Ratio
Valuation
37.3x 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
117.0x 64.5x Lower Multiple DXR
Revenue Growth (YoY)
Growth
+21.5% +25.5% Higher Growth DXR
Operating Margin (TTM)
Profitability
6.0% -5894.3% Higher Margin BLFS
Net Profit Margin
Profitability
54.4% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
12.8% 14.2% Higher ROE DXR
52-Week Range Position
Momentum
95% ($18–$40) 2% ($8–$15) Stronger Trend BLFS
Beta / 30D Volatility
Risk Regime
1.05β · 31% Vol 0.28β · 32% Vol Lower Realized Risk BLFS
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$107M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.2M ($8.3M Net Cash) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLFS +7.91 pp
BLFS: +8.67% · DXR: +0.76%
3M Horizon BLFS +28.62 pp
BLFS: +34.67% · DXR: +6.05%
6M Horizon BLFS +107.66 pp
BLFS: +104.83% · DXR: -2.83%
1Y Horizon BLFS +60.98 pp
BLFS: +39.49% · DXR: -21.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLFS vs DXR. Trailing 12-month operating profitability (BLFS 6.0% vs DXR -5894.3%) and valuation multiples (BLFS 117.0x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

BLFS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$107M
Gross Margin63.6%
Op. Margin6.0%
ROE / Fwd P/E12.8% · 117.0x
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLFS BREAKOUT
38d in phase · OBV ACCUMULATION
Current IV 40.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLFS Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.8B market capitalization and 6.0% operating margin.
OpEx & R&D Reinvestment 57.6% of Rev ($61M)
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BLFS vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over BioLife Solutions Inc. (BLFS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLFS carries a Unified Composite Score of 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Technical & Structure Timing Caution: BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: BLFS posts +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, BLFS generates $107M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, BLFS deploys 57.6% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

DXR screens cheaper on headline valuation multiples. BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLFS (12.8% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.